| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4319fe3d827bd24add491d4ed90e7692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b82f96f476d23a7668947a83cdaefcc4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 |
| filingDate |
2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_907f647b86f9230f07c800508df545c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7cb5de8913a2559c6024c3c4492df02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7df878ed28ec4035d83519851c3964a |
| publicationDate |
2018-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018000066-A1 |
| titleOfInvention |
Platelet Protection Solution Having Beta-Galactosidase and Sialidase Inhibitors |
| abstract |
The present invention relates to a platelet protection solution (PPS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020047157-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11541105-B2 |
| priorityDate |
2011-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |